NSG 527 ADVANCED PHARMACOLOGY
COMPREHENSIVE EXAM QUESTIONS
AND ANSWERS
1. A patient with chronic kidney disease (CKD) requires an antibiotic that is primarily excreted
renally. Which pharmacokinetic parameter is most significantly affected, necessitating a dose
adjustment?
A. Volume of distribution
B. Absorption rate
C. Half-life (t1/2)
D. Protein binding
Answer: C
Conceptual Explanation: In renal impairment, the clearance of renally excreted drugs
decreases, which directly increases the half-life of the drug, requiring a dose reduction or
interval extension.
,2. When prescribing a drug that is a strong inducer of the CYP3A4 enzyme, what effect should
the provider anticipate on a co-administered substrate of the same enzyme?
A. Increased serum concentration of the substrate
B. Decreased serum concentration of the substrate
C. Decreased metabolism of the substrate
D. No change in the substrate concentration
Answer: B
Conceptual Explanation: Enzyme inducers increase the metabolic activity of the CYP450
system, leading to faster breakdown and decreased plasma levels of the substrate drug.
3. Which of the following describes the ‘First-Pass Effect’ in pharmacology?
A. The rapid distribution of drugs to the brain
B. Excretion of the drug through the kidneys on the first cycle
C. Metabolism of a drug by the liver before it reaches systemic circulation
D. The binding of a drug to plasma proteins
Answer: C
Conceptual Explanation: The first-pass effect refers to the initial metabolism in the liver
of a drug absorbed from the gastrointestinal tract before the drug reaches systemic
circulation.
, 4. A 65-year-old patient is prescribed a new medication that is highly protein-bound. The
patient has low serum albumin. What is the primary concern for this patient?
A. The drug will be ineffective
B. Rapid excretion of the drug
C. Decreased absorption of the drug
D. Increased risk of drug toxicity due to higher free drug levels
Answer: D
Conceptual Explanation: Drugs that are highly protein-bound compete for albumin. Low
albumin levels mean fewer binding sites, resulting in higher levels of ‘free’ (active) drug,
which increases the risk of toxicity.
5. Which medication is classified as a ‘prodrug’, requiring metabolic activation in the liver?
A. Lisinopril
B. Warfarin
C. Clopidogrel
D. Metformin
Answer: C
Conceptual Explanation: Clopidogrel is a prodrug that must be metabolized by CYP2C19
into its active metabolite to inhibit platelet aggregation.
COMPREHENSIVE EXAM QUESTIONS
AND ANSWERS
1. A patient with chronic kidney disease (CKD) requires an antibiotic that is primarily excreted
renally. Which pharmacokinetic parameter is most significantly affected, necessitating a dose
adjustment?
A. Volume of distribution
B. Absorption rate
C. Half-life (t1/2)
D. Protein binding
Answer: C
Conceptual Explanation: In renal impairment, the clearance of renally excreted drugs
decreases, which directly increases the half-life of the drug, requiring a dose reduction or
interval extension.
,2. When prescribing a drug that is a strong inducer of the CYP3A4 enzyme, what effect should
the provider anticipate on a co-administered substrate of the same enzyme?
A. Increased serum concentration of the substrate
B. Decreased serum concentration of the substrate
C. Decreased metabolism of the substrate
D. No change in the substrate concentration
Answer: B
Conceptual Explanation: Enzyme inducers increase the metabolic activity of the CYP450
system, leading to faster breakdown and decreased plasma levels of the substrate drug.
3. Which of the following describes the ‘First-Pass Effect’ in pharmacology?
A. The rapid distribution of drugs to the brain
B. Excretion of the drug through the kidneys on the first cycle
C. Metabolism of a drug by the liver before it reaches systemic circulation
D. The binding of a drug to plasma proteins
Answer: C
Conceptual Explanation: The first-pass effect refers to the initial metabolism in the liver
of a drug absorbed from the gastrointestinal tract before the drug reaches systemic
circulation.
, 4. A 65-year-old patient is prescribed a new medication that is highly protein-bound. The
patient has low serum albumin. What is the primary concern for this patient?
A. The drug will be ineffective
B. Rapid excretion of the drug
C. Decreased absorption of the drug
D. Increased risk of drug toxicity due to higher free drug levels
Answer: D
Conceptual Explanation: Drugs that are highly protein-bound compete for albumin. Low
albumin levels mean fewer binding sites, resulting in higher levels of ‘free’ (active) drug,
which increases the risk of toxicity.
5. Which medication is classified as a ‘prodrug’, requiring metabolic activation in the liver?
A. Lisinopril
B. Warfarin
C. Clopidogrel
D. Metformin
Answer: C
Conceptual Explanation: Clopidogrel is a prodrug that must be metabolized by CYP2C19
into its active metabolite to inhibit platelet aggregation.
